Keywords:
Aptamer; autophagy; cancer stem cells; CD133; doxorubicin; hepatocellular carcinoma
Abstract:
Doxorubicin is the most frequently used chemotherapeutic agent for the treatment of hepatocellular carcinoma. However, one major obstacle to the effective management of liver cancer is the drug resistance derived from the cancer stem cells.